EMEA-003333-PIP01-22 - paediatric investigation plan

Hemopexin

Key facts

• Active substance:
  Hemopexin
• Therapeutic area:
  Congenital, familial and genetic disorders
• Decision number:
  P/0141/2024
• PIP number:
  EMEA-003333-PIP01-22
• Pharmaceutical form(s):
  Solution for infusion
• Condition(s) / indication(s):
  Treatment of sickle cell disease
• Route(s) of administration:
  Intravenous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  06/05/2024
• Compliance check done:
  No

Decision

P/0141/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for hemopexin, human, (EMEA-003333-PIP01-22)

Adopted Reference Number: EMA/153127/2024